Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer.

Nature cancer - 1 Feb 2022

Gavert Nancy, Zwang Yaara, Weiser Roi, Greenberg Orli, Halperin Sharon, Jacobi Oded, Mallel Giuseppe, Sandler Oded, Berger Adi Jacob, Stossel Erez, Rotin Daniil, Grinshpun Albert, Kamer Iris, Bar Jair, Pines Guy, Saidian Daniel, Bar Ilan, Golan Shay, Rosenbaum Eli, Nadu Andrei, Ben-Ami Eytan, Weitzen Rony, Nechushtan Hovav, Golan Talia, Brenner Baruch, Nissan Aviram, Margalit Ofer, Hershkovitz Dov, Lahat Guy, Straussman Ravid

Abstract excerpt

Translating preclinical studies to effective treatment protocols and identifying specific therapeutic responses in individuals with cancer is challenging. This may arise due to the complex genetic makeup of tumor cells and the impact of their multifaceted tumor microenvironment on drug response. To find new clinically relevant drug combinations for colorectal cancer (CRC), we prioritized the top five synergistic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to Colorectal Neoplasms

Share to Mitogen-Activated Protein Kinase Kinases

Share to Mutation

Share to Tumor Microenvironment

Source

Identifiers

PMID: 35145327
DOI: 10.1038/s43018-021-00325-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer.PMID 35145327Read ↗

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screeningSemantic proximity Read ↗

Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer typesSemantic proximity Read ↗

High-throughput screening reveals higher synergistic effect of MEK inhibitor combinations in colon cancer spheroidsSemantic proximity Read ↗

Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor modelsSemantic proximity Read ↗

BRAFV600E patient derived colon cancer organoids identify biomarkers of response to EGFR and BRAF inhibition and replicate clinical data.Semantic proximity Read ↗

An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapySemantic proximity Read ↗

XENTURION, a multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients for population-level translational oncologySemantic proximity Read ↗

Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer.Semantic proximity Read ↗

Heterogeneity, Inherent and Acquired Drug Resistance in Patient-Derived Organoids Models of Primary Liver CancerSemantic proximity Read ↗

Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapySemantic proximity Read ↗

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.Semantic proximity Read ↗

Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.